Evidence map›Paper›PMID 29740809›Full record

Trial reportBritish journal of haematology2018

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

Elizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, Tianqi Chen, Carol Ann Huff, Frank G Basile, Philip M Wade, Claudia E Paba-Prada, Irene M Ghobrial, Robert L Schlossman and 9 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04009109 (A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma), which is not on this map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04009109 phase2active not recruitingnot on this mapstarted 2020, after this paper: background citation

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

TypeinterventionalSponsorAlliance Foundation Trials, LLC.Ran2020 to 2027Enrolled79ConditionsMyeloma, MultipleArmsLenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Review
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Elizabeth K O'DonnellMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0002-4042-1526
Jacob P LaubachHarvard Medical School, Boston, MA, USA.
Andrew J YeeMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Tianqi ChenDana-Farber Cancer Institute, Boston, MA, USA.
Carol Ann HuffJohns Hopkins Hospital, Baltimore, MD, USA.
Frank G BasileCape Cod Hospital, Hyannis, MA, USA.
Philip M WadeCape Cod Hospital, Hyannis, MA, USA.
Claudia E Paba-PradaHarvard Medical School, Boston, MA, USA.
Irene M GhobrialHarvard Medical School, Boston, MA, USA.
Robert L SchlossmanHarvard Medical School, Boston, MA, USA.
Jill N BurkeMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Cynthia C HarringtonMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Kathleen J LivelyMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Hannah F LyonsMass General/North Shore Cancer Center, Danvers, MA, USA.
Nikhil C MunshiHarvard Medical School, Boston, MA, USA.
Kenneth C AndersonHarvard Medical School, Boston, MA, USA.
Lorenzo TrippaDana-Farber Cancer Institute, Boston, MA, USA.
Paul G RichardsonHarvard Medical School, Boston, MA, USA.ORCID 0000-0002-7426-8865
Noopur S RajeMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Harvard University · USMassachusetts General Hospital · USCape Cod Hospital · USDana-Farber Cancer Institute · USJohns Hopkins Hospital · USNorth Shore Community College · US

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
NCI NIH HHS P01 CA155258
6 · The paper itself

Abstract

We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m

Indexed as

Administration, CutaneousAdministration, OralAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDisease-Free SurvivalDrug Administration ScheduleFemaleHumansKaplan-Meier EstimateLenalidomideMaleMultiple MyelomaPatient Reported Outcome MeasuresBortezomibDexamethasoneLenalidomidemultiple myelomatransplant-ineligible

Identifiers

PMID29740809
PMCPMC6074026
OpenAlexW2802890120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.